We are live on ! Find out more
TOBAM

TOBAM Portfolio holdings

AUM $244M Turnover 23.99%
1-Year Est. Return 22.99%
This Fund
S&P 500
This Quarter Est. Return
-7.74%
1 Year Est. Return
+22.99%
3 Year Est. Return
+76.51%
5 Year Est. Return
+69.97%
10 Year Est. Return
+288.16%
AUM
$1.6B
AUM Growth
-$392M
Cap. Flow
-$203M
Cap. Flow %
-12.69%
Top 10 Hldgs %
25.61%
Holding
503
New
74
Increased
178
Reduced
101
Closed
74
Avg Time Held
1.6 years
Top 10 Avg Time Held
0.8 years
Top 20 Avg Time Held
1.4 years

Top Buys

Rank Stock Value
1
DGX icon
Quest Diagnostics
DGX
+$24.5M
2
CHD icon
Church & Dwight
CHD
+$19.6M
3
ES icon
Eversource Energy
ES
+$18.2M
4
EXPE icon
Expedia Group
EXPE
+$17.6M
5
KMB icon
Kimberly-Clark
KMB
+$17.5M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$31.2M
2
CAG icon
Conagra Brands
CAG
+$27M
3
SEE icon
Sealed Air
SEE
+$22.8M
4
LLY icon
Eli Lilly
LLY
+$22.1M
5
REG icon
Regency Centers
REG
+$20.3M

Sector Composition

Rank Sector Weight
1 Healthcare 28%
2 Consumer Staples 25.89%
3 Communication Services 10.3%
4 Technology 7.09%
5 Materials 6.85%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
PFE icon
1
Pfizer
PFE
$160B
$46.4M 2.91%
885,098
-149,451
-14% -$7.62M
2020 Q3
7 quarters
GIS icon
2
General Mills
GIS
$18.5B
$44.9M 2.81%
594,592
-243,263
-29% -$17M
2018 Q3
15 quarters
KMB icon
3
Kimberly-Clark
KMB
$65.8B
$43.7M 2.74%
323,296
+132,681
+70% +$17.5M
2020 Q3
7 quarters
MRK icon
4
Merck
MRK
$340B
$43.6M 2.73%
477,807
+119,071
+33% +$10.6M
2020 Q3
7 quarters
K icon
5
DELISTED
Kellanova
K
$40.7M 2.55%
607,318
-167,756
-22% -$10.9M
2016 Q1
25 quarters
CLX icon
6
Clorox
CLX
$13.1B
$40.7M 2.55%
288,398
-50,947
-15% -$7.28M
2014 Q3
31 quarters
BDX icon
7
Becton Dickinson
BDX
$58.9B
$37.8M 2.37%
153,221
-11,385
-7% -$2.89M
2020 Q2
8 quarters
HRL icon
8
Hormel Foods
HRL
$12.7B
$37.7M 2.36%
796,098
-84,912
-10% -$4.24M
2020 Q2
8 quarters
SJM icon
9
J.M. Smucker
SJM
$14.3B
$37.1M 2.32%
289,743
-41,656
-13% -$5.56M
2018 Q4
14 quarters
EA icon
10
DELISTED
Electronic Arts
EA
$36.3M 2.27%
298,330
+96,482
+48% +$12.3M
2020 Q2
8 quarters
GEN icon
11
Gen Digital
GEN
$18.1B
$36.2M 2.27%
1,650,117
+46,097
+3% +$1.13M
2018 Q2
16 quarters
CHD icon
12
Church & Dwight
CHD
$26.4B
$35.9M 2.25%
387,276
+207,082
+115% +$19.6M
2018 Q1
17 quarters
LLY icon
13
Eli Lilly
LLY
$1.23T
$35.9M 2.25%
110,650
-73,636
-40% -$22.1M
2020 Q3
7 quarters
CHRW icon
14
C.H. Robinson
CHRW
$16B
$35.9M 2.25%
353,763
+75,367
+27% +$7.87M
2019 Q4
10 quarters
DGX icon
15
Quest Diagnostics
DGX
$28.6B
$34.5M 2.16%
259,352
+179,847
+226% +$24.5M
2020 Q3
7 quarters
BIIB icon
16
Biogen
BIIB
$37.2B
$33M 2.07%
161,853
-15,840
-9% -$3.24M
2019 Q1
13 quarters
CPB icon
17
Campbell's
CPB
$7.29B
$33M 2.07%
686,574
-198,320
-22% -$9.34M
2016 Q2
24 quarters
NEM icon
18
Newmont
NEM
$109B
$30.7M 1.93%
515,246
+70,468
+16% +$4.99M
2013 Q2
36 quarters
NBIX icon
19
Neurocrine Biosciences
NBIX
$16.5B
$29.9M 1.87%
306,494
+90,037
+42% +$8.31M
2018 Q4
14 quarters
ED icon
20
Consolidated Edison
ED
$44.3B
$28.2M 1.77%
296,158
-51,414
-15% -$4.9M
2014 Q4
30 quarters
DLTR icon
21
Dollar Tree
DLTR
$26.7B
$27.7M 1.73%
177,463
-103,667
-37% -$16.4M
2019 Q1
13 quarters
ALNY icon
22
Alnylam Pharmaceuticals
ALNY
$20B
$26.3M 1.65%
180,101
+24,516
+16% +$3.48M
2020 Q2
8 quarters
FNV icon
23
Franco-Nevada
FNV
$45.8B
$22.2M 1.39%
169,313
-47,172
-22% -$6.98M
2013 Q2
36 quarters
AIZ icon
24
Assurant
AIZ
$15.7B
$21.3M 1.33%
123,020
-50,886
-29% -$9.22M
2022 Q1
1 quarter
MRNA icon
25
Moderna
MRNA
$79.6B
$21M 1.31%
146,771
-7,406
-5% -$1.06M
2020 Q2
8 quarters

Similar funds

TOBAM's Q2 2022 Portfolio in Review

As of Q2 2022, TOBAM held 503 positions worth $1.6B, down 20% from $1.99B the previous quarter. Its ten largest holdings account for 26% of the portfolio.

TOBAM withdrew a net $203M in Q2 2022, closing 74 positions and reducing 101 holdings. Its most notable exit was Novavax, an estimated $12.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 28% of assets, up from 26% a quarter earlier, followed by Consumer Staples and Communication Services.

Against the trend, TOBAM opened a new position in Expedia Group worth $11.8M.

  • TOBAM's largest Q2 2022 buy was Expedia Group: 124,451 shares worth $11.8M.
  • TOBAM added most to Quest Diagnostics in Q2 2022, an estimated $24.5M increase.
  • TOBAM's biggest Q2 2022 reduction was Gilead Sciences, cutting an estimated $31.2M.
  • TOBAM fully exited Novavax in Q2 2022, selling an estimated $12.8M.
  • TOBAM's ten largest holdings make up 26% of its $1.6B portfolio in Q2 2022.
  • TOBAM opened 74 new positions and closed 74 in Q2 2022.
  • TOBAM's portfolio value fell 20% quarter-over-quarter to $1.6B.

Based on TOBAM's 13F filing for Q2 2022, filed 2 Aug 2022.